Metaplastic breast cancer: Clinicopathological features and its prognosis

Journal of Clinical Pathology

Volumn 65, Issue 5, 2012, Pages 441-446

  Lee, Hyewon ^a   Jung, So Youn ^a   Ro, Jae Yun ^a   Kwon, Youngmee ^a   Sohn, Joo Hyuk ^b   Park, In Hae ^a   Lee, Keun Seok ^a   Lee, Seeyoun ^a   Kim, Seok Won ^a   Kang, Han Sung ^a   Ko, Kyoung Lan ^a   Ro, Jungsil ^a  

^a National Cancer Center   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; TAXANE DERIVATIVE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; KOREA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METAPLASTIC BREAST CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIPLE NEGATIVE INVASIVE DUCTAL CARCINOMA; TUMOR VOLUME;

BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; MASTECTOMY, SEGMENTAL; METAPLASIA; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REPUBLIC OF KOREA; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84862826081     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200586     Document Type: Article

References (28)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
2. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34. (Pubitemid 46698581)
3. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-7. (Pubitemid 46631305)
4. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109:1721-8. (Pubitemid 46668532)
5. Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinomaerare types: review of the literature. Ann Oncol 2009;20:1763-70.
6. Huvos AG, Lucas JC Jr, Foote FW Jr. Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med 1973;73:1078-82.
7. Lien HC, Hsiao YH, Lin YS, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 2007;26:7859-71. (Pubitemid 350261788)
8. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to- mesenchymal transition and stem cell characteristics. Cancer Res 2009;69:4116-24.
9. Jung SY, Kim HY, Nam BH, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat 2010;120:627-37.
10. Henson DE, Ries L, Freedman LS, et al. Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index. Cancer 1991;68:2142-9.
11. Edge SB, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th edn. New York: Springer, 2010.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
13. Bellino R, Arisio R, D'Addato F, et al. Metaplastic breast carcinoma: pathology and clinical outcome. Anticancer Res 2003;23:669-73. (Pubitemid 36358470)
14. Chao TC, Wang CS, Chen SC, et al. Metaplastic carcinomas of the breast. J Surg Oncol 1999;71:220-5.
15. Luini A, Aguilar M, Gatti G, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 2007;101:349-53. (Pubitemid 46169889)
16. Tseng WH, Martinez SR. Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol 2011;18:94-103.
17. Okada N, Hasebe T, Iwasaki M, et al. Metaplastic carcinoma of the breast. Hum Pathol 2010;41:960-70.
18. Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol 1989;20:732-40. (Pubitemid 19203633)
19. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 1989;64:1490-9.
20. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol 1989;20:628-35. (Pubitemid 19185291)
21. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 1990;21:1142-50. (Pubitemid 20381997)
22. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 1990;65:272-6. (Pubitemid 20035352)
23. Oberman HA. Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol 1987;11:918-29. (Pubitemid 18011643)
24. Tavassoli FA, Devilee P, eds. The WHO Classification of Tumors. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC press, 2003.
25. Yamaguchi R, Horii R, Maeda I, et al. Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications. Hum Pathol 2010;41:679-85.
26. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
27. Rayson D, Adjei AA, Suman VJ, et al. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol 1999;10:413-19. (Pubitemid 29236418)
28. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009;20:1319-29.